Your browser doesn't support javascript.
loading
Population Pharmacokinetic Analyses for Ertapenem in Subjects with a Wide Range of Body Sizes.
Lakota, Elizabeth A; Landersdorfer, Cornelia B; Zhang, Li; Nafziger, Anne N; Bertino, Joseph S; Bhavnani, Sujata M; Forrest, Alan.
Afiliación
  • Lakota EA; Institute for Clinical Pharmacodynamics, Schenectady, New York, USA elakota@icpd.com.
  • Landersdorfer CB; Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Victoria, Australia.
  • Zhang L; Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Victoria, Australia.
  • Nafziger AN; Sanofi, Bridgewater, New Jersey, USA.
  • Bertino JS; Bertino Consulting, Schenectady, New York, USA.
  • Bhavnani SM; Bertino Consulting, Schenectady, New York, USA.
  • Forrest A; Institute for Clinical Pharmacodynamics, Schenectady, New York, USA.
Antimicrob Agents Chemother ; 62(10)2018 10.
Article en En | MEDLINE | ID: mdl-30061283
Despite a number of studies reporting that ertapenem pharmacokinetic parameters differ considerably in obese patients from those in healthy volunteers, functions describing the relationships between this agent's pharmacokinetics and indicators of body size have not been developed. The aim of this analysis was to develop an ertapenem population pharmacokinetic model using data from a previously described study in normal-weight, obese, and morbidly obese healthy volunteers. A single ertapenem 1-g dose administered intravenously was evaluated in 30 subjects within different body mass index (BMI) categories. The population pharmacokinetic model was developed using the first-order conditional estimation method with interaction (FOCE-I) algorithm within NONMEM. The ability of age, sex, renal function, and various body size measures (total body weight, height, body mass index, ideal body weight, fat-free mass, and body surface area [BSA]) to explain a portion of the interindividual variability on select pharmacokinetic parameters was explored using stepwise forward selection (α = 0.01) and backward elimination (α = 0.001). The data were best described using a linear three-compartment model with total body weight as a covariate on clearance (CL = 1.79 · [weight/95.90]0.278) and BSA as a covariate on central volume (Vc = 4.76 · [BSA/2.06]1.86). After accounting for fixed effects, the estimated interindividual variability was very low (<10% for all clearance and volume terms). Goodness-of-fit diagnostics indicated a precise and unbiased fit to the data. Using the developed population pharmacokinetic model and simulation, reliable estimates of ertapenem serum exposures, which can be utilized to evaluate various dosing regimens in subjects with a wide range of body sizes, are expected.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ertapenem Límite: Adult / Female / Humans / Male Idioma: En Revista: Antimicrob Agents Chemother Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ertapenem Límite: Adult / Female / Humans / Male Idioma: En Revista: Antimicrob Agents Chemother Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos